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ABSTRACT 
 
Objective: To explore what influences engagement with Option B+ in four sub-Saharan African 
settings.   
Methods: In-depth interviews were conducted in 2015, with 22 HIV-positive women who had been 
pregnant since Option B+ was available, and 15 health-care workers (HCW) involved in HIV service 
delivery.  Participants were purposely selected from four health and demographic surveillance sites 
in Malawi, Tanzania and Uganda.  A thematic content analysis was conducted to investigate what 
influenced engagement with Option B+. 
Results: Feeling ‘ready’ was key to pregnant women accepting anti-retroviral treatment (ART) on the 
same day as diagnosis at ante-natal clinic, this was influenced by previous knowledge of HIV-positive 
status, interactions with HCWs and relationship with their partners.  The desire to protect their 
unborn infant was the main issue that motivated women to initiate treatment, temporarily 
overriding barriers to starting ART.  Many HCWs recognised that pressurising women into starting 
ART may lead them to stop treatment following delivery.  However, their own responsibility to 
protect the infant sometimes drove HCWs to use strong persuasive techniques to initiate pregnant 
women onto ART as early as possible, occasionally causing women to disengage. 
Conclusion:  Protecting the baby superseded feelings of unpreparedness for life-long ART and may 
explain poor retention observed in Option B+ programmes. Women may benefit from more time to 
accept their status, and counselling on the longer-term value of ART beyond the pregnancy and 
breastfeeding period.  Strategies to promote readiness for same-day initiation of life-long treatment 
are urgently needed, and may provide important lessons for universal test-and-treat 
implementation. 
 
 
 
 
 
  
KEY MESSAGES 
 Readiness to start ART while pregnant depended on multiple factors; however the drive to 
protect the unborn child enabled many women to temporarily overcome all other barriers. 
 Health-care workers were aware of the challenges of accepting Option B+, but their desire to 
protect the infants and comply with policy obligated them to adopt strong persuasive 
tactics. 
 Without this motivation, newly diagnosed patients expected to start ART immediately 
through ‘test-and-treat’ programmes may find barriers to starting treatment more difficult 
to overcome. 
 
 
BACKGROUND 
 
Initiating pregnant and breast-feeding women on life-long antiretroviral therapy (ART) regardless of 
clinical stage or CD4 count (Option B+) was expected to ease the burden on health services by 
removing the need to manage ART interruptions, and to protect women’s partners and future 
pregnancies by reducing viral rebounds.[1] Option B+ was devised and implemented by Malawi in 
2011, it was incorporated into World Health Organisation guidelines in 2012[2] and implemented by 
several other African countries, including Uganda and Tanzania, in 2013.[3]   
 
Programmatic evaluations of Option B+ in many African settings have indicated higher rates of 
enrolment,[3–5] but higher levels of attrition within the first year, leading to poorer retention in care 
compared to programmes for women who start ART for their own health.[6–8]  Low retention 
presents challenges for meeting the UNAIDS ‘90-90-90’ targets[9] and may lead to drug resistance, 
increasing the risks of treatment failure if women reinitiate ART later. 
 
Qualitative studies exploring social and contextual factors surrounding the acceptance and retention 
of Option B+ have identified fear of involuntary disclosure of HIV status, difficulties with clinic staff, 
transportation issues and lack of support from partners as key barriers.[10–13]  These issues 
resonate with findings from studies exploring engagement with HIV services among non-pregnant 
people living with HIV (PLHIV).[14] It is therefore not apparent why patterns of uptake and 
adherence differ among women who initiate ART under Option B+ compared to women in standard 
ART programmes. Furthermore, few studies have explicitly explored how psychosocial issues relating 
to pregnancy interplay with these factors. 
 ‘Test-and-treat’ policies are being rolled out in many African countries,[15] which will involve ART-
initiation for all PLHIV immediately following an HIV-diagnosis regardless of their immunological 
status, many of whom will not have had AIDS symptoms.  As there are parallels between these 
asymptomatic PLHIV and pregnant women being asked to accept Option B+, it may be possible to 
use these women’s experiences to help guide implementation of ‘test-and-treat’. 
 
In this paper, we aim to understand what influences acceptance and adherence to Option B+, and 
explore whether these influences are specific to pregnancy, using data from a multi-country 
qualitative study in rural areas of Malawi, Tanzania and Uganda.  
  
Theoretical perspectives 
 
A socio-ecological model[16] extended to include additional psychosocial dimensions (figure 1) has 
previously been used to explore factors relating to uptake and retention on ART in PLHIV.[17]  In our 
analysis, we draw from this framework to disentangle the specific issues relating to pregnancy and 
medication-taking when living without symptoms of HIV-related illnesses.   
 
METHODS 
 
Data for this analysis were drawn from the Bottlenecks Study undertaken in seven health and 
demographic surveillance sites (HDSS) across six countries in Eastern and Southern Africa within the 
ALPHA network (http://alpha.lshtm.ac.uk/). The aim of the broader study was to understand how 
differences in HIV policy and programme implementation influence the health care-seeking 
experiences of PLHIV in Eastern and Southern Africa.   
 
Study settings 
 
This paper presents a sub-section of the Bottlenecks data from settings where Option B+ women 
were interviewed: Karonga (Malawi), Kisesa (Tanzania), Kyamulibwa and Rakai (Uganda), where HIV 
prevalence since ART was available was 7.4%, 5.6%, 6.6% and 12.6% respectively.[19] Crude fertility 
rates per 1000 since ART was available were 158.3 in Kisesa, 149.7 in Kyamulibwa[20] and 166.1 in 
Karonga (personal communication). Option B+ was available in Karonga in 2012, in Kyamulibwa and 
Rakai in 2013, and in Kisesa in 2014. All four study locations are rural, with most residents involved 
in subsistence farming.  
 
Sampling frame and participants 
 
A sampling frame of PLHIV was drawn up in each setting using HDSS records, clinic data and 
screening tools.  Participants were then purposively-selected to include those who had not yet 
initiated ART, had been on ART for various lengths of time or were lost to follow-up.  For this sub-
study, all 22 female participants who were pregnant, or had been since Option B+ had been 
available, were included: nine from Malawi, five from Tanzania and nine from Uganda. The median 
age of these participants was 30, with a median of three live births, 16 were in relationships, and 
two reported taking ART previously.  Health-care workers (HCW) involved in providing HIV care at 
local clinics were purposively-sampled; 15 were included in this analysis. There were no refusals to 
participate, however one interview in Malawi was cut short when the woman did not want to 
continue. 
 
Data collection 
 
Due to the sensitive and personal nature of information to be discussed, face-to-face in-depth 
interviews (IDIs) were used.  The IDIs were conducted in 2015, by experienced research assistants in 
the local languages (Swahili in Kisesa, Tumbuka in Karonga and Luganda in Rakai and Kyamulibwa).  
IDIs lasted 60-90 minutes on average, and were conducted in private at participants’ homes or in the 
clinics. Topic guides covered social and economic circumstances and experiences of using or 
providing HIV care and treatment services, including during pregnancy.  Field notes were taken and 
IDIs were audio-recorded, and were translated to English verbatim (Karonga, Kisesa, Rakai) or 
summarised into detailed reports (Kyamulibwa) by research assistants.  Transcripts/reports were 
anonymised and all data stored in secure password-protected locations.  Participants were recruited 
until data saturation was reached; IDIs were repeated occasionally to explore certain topics in more 
detail.  Additional methodological details concerning the Bottlenecks study can be found in an online 
only supplement (LINK TO SUPPLEMENT HERE). 
 
Analysis 
 
An initial thematic content analysis was conducted by each local study coordinator who coded the 
data, assisted by NVivo 10 or 11 in Karonga, Kisesa and Rakai and conducted manually in 
Kyamulibwa.  Emerging themes based on experiences, opinions and understanding of Option B+ 
were summarised in tables.  Summary tables from each of the four settings were compiled and raw 
transcripts/summaries were used to expand on relevant thematic areas.  The emerging themes were 
compared with the expanded socio-economic framework (figure 1); relevant elements of this 
framework plus additional important themes were then used to create a framework specific to this 
population. 
 
 
Ethics 
 
This study was approved by ethical review boards in each country and at the London School of 
Hygiene and Tropical Medicine. 
 
 
RESULTS 
 
Several interrelated themes that went beyond the extended socio-economic model emerged from 
our analysis to explain engagement with HIV-treatment among pregnant women in the four settings 
(figure 2). 
 
The role of pregnancy in motivating ART initiation 
 
For most participants, the prevailing motivation driving uptake and adherence to Option B+ was to 
protect the unborn child from HIV, and to stay alive to support the child after birth.   
 
“I felt uncomfortable [following HIV diagnosis] but they told me that I should not feel bad 
about it. They assured me that I would be able to have a child without HIV.” (PLHIV-accepted 
B+ but defaulted after birth, Uganda) 
 
"I wanted to start on the treatment earlier to deliver a baby free of HIV" (PLHIV-accepted B+, 
retained, Uganda) 
 
HCWs recognised this driving force to protect the child and some expressed concerns that women 
would discontinue taking ART once they had weaned the baby. 
 
“… when they get to know the HIV negative status of their children, they do not go back for 
more treatment and care: they only think about the health of the children and forget about 
theirs” (HCW, Uganda) 
 
No patient or HCW mentioned protecting subsequent pregnancies and the health of the woman was 
rarely mentioned.  Few noted the additional benefit of Option B+ in reducing risk of transmission to 
HIV-negative partners.  
 
The readiness of women to accept Option B+ 
 
 
 
Women who first tested positive at the ANC often found it difficult to accept starting ART. This was 
recognised by HCWs, who also suggested that those who were young, in their first pregnancy, or 
lacking support were the most vulnerable, as in this example of a 15 year-old girl:  
  
“...we diagnosed her with HIV and we advised her to start taking ARVs, but that girl refused 
and tore her health passport because it was an unexpected thing to her...” (HCW, Malawi) 
 
Conversely, women who found it easier to accept the need for ART had often already come to terms 
with their positive status, like this woman who had tested multiple times in different places before 
believing the result, reporting that "…I just felt that I am ready to start taking them [ART] because...I 
took the test, in all the places for about four times... I just realized that I have to take them." (PLHIV-
accepted B+ & retained, Tanzania). 
 
In each country, policy states that pregnant women can choose to opt out of HIV-testing and 
treatment. However, most women believed that HIV testing and ART initiation was an obligatory 
part of ante-natal clinic (ANC). 
 
"The nurse tested my blood as it is an instruction of the hospitals to test pregnant women.  
She found that I had a sickness [HIV] which deserved that treatment, so I had no alternative... 
I accepted to take the drugs, because I had no option" (PLHIV-accepted B+ & retained, 
Uganda) 
 
The majority of HCWs recognised that receiving an HIV-diagnosis and having to start ART 
immediately “is not an easy situation…she can’t just receive it abruptly” (HCW, Tanzania).   HCWs 
reported that in general women went through the counselling processes with no issues, however 
many also felt that “we need to give people time to take a decision. We may force them to begin HIV 
treatment and they refuse to take the medicine as prescribed” (HCW, Uganda).  Despite these 
sentiments most HCWs felt bound by the policy to start all eligible women on ART on the same day:  
 
“...we ask that person the reasons she doesn’t want to test once she has explained to me the 
reasons, I refer that person to my friend since we have different ways of handling people you 
may find that she accept to be tested.  If they are not on ART we counsel them and tell them 
the reasons why we are doing that up until they accept... From there we also go together to 
the clinic I always make sure she gets there. They don’t go alone [to start ART] because if you 
can send them alone sometimes they cannot go” (HCW, Malawi) 
 
“If they decline HIV testing, we tell them that they cannot get treatment from our facility” 
(HCW, Uganda). 
 
 
Pregnant women who did not feel ready to initiate ART described various avoidance tactics; such as 
accepting then discarding treatment, providing false information so they couldn’t be followed up or 
switching ANC by obtaining new health documents. These behaviours were well-known to HCWs in 
all settings. 
 
“Yes I was tested [at first ANC] and found positive again and I was told to go to [hospital] to 
start ART because at [first ANC] there were no ARVs…I didn’t go I then went to [second ANC] 
because I had backache they asked me if I already started ANC I said no … I then tested 
positive and was told to start ART. At [second ANC] I went with another Health passport not 
the one I was using at [first ANC].” (PLHIV-accepted B+ but defaulted while still pregnant, 
Malawi) 
 
The effect of inter-personal interactions on acceptance of Option B+ 
 Women’s relationships with the HCWs were generally reported to be good by both women and 
HCWs.  However, the recounts of women illustrated a clear power-hierarchy and little two-way 
communication.   While many women accepted what they were told without question, some 
complained reporting they “were not taught anything” (PLHIV-did not accept B+, Malawi) or “did not 
get any counselling” (PLHIV-accepted B+, still pregnant or breast-feeding, Uganda), or that the HCWs 
shouted at them if they missed appointments.  These interactions served as drivers to some who felt 
obliged to follow the ‘rules’ but as barriers to others, who opted to disengage with care completely.   
 
Additionally perceived or actual support from male partners emerged as a factor in determining 
whether a woman accepted Option B+ or not.  When a woman’s husband was supportive he was 
often also HIV-positive (or suspected it).  Some women with supportive partners reported 
themselves as the lucky ones as “some men are abusive but my husband does not do that” (PLHIV-
accepted B+ but defaulted after birth, Uganda).  In all settings there were examples of unsupportive 
partners.  Some pregnant women were not taking ART due to their husband disallowing them, as 
explained by this woman:  
 
“…there were quarrels with my husband in my house: he said ‘I don’t know about HIV’, that is 
why I have stayed without going to hospital until now.”  (PLHIV-did not accept B+, Malawi).   
 
 
DISCUSSION 
 
Our qualitative study in four rural African settings found that the psychosocial factor of feeling 
‘ready’ was key to being able to accept ART on the same day as diagnosis at ANC.  This was 
influenced by many factors, including previous knowledge of their HIV-positive status, interactions 
with HCWs and the relationship with their partner.  Underpinning all of this remained the driving 
influence of the pregnancy and role as a mother (figure 2).  Pregnancy may result in women 
accepting ART before they feel ‘ready’ then stopping treatment once its influence has passed.  The 
limitations of the extended socio-ecological model amongst this population illustrates the potential 
differences between pregnant women and non-pregnant PLHIV.  This difference could explain the 
high level of loss to follow up in the first few months after uptake of Option B+ observed in recent 
quantitative studies.[8] 
 
The importance of women feeling ready to start ART was mentioned by HCWs and women in all 
settings.  Accepting a positive result took time, and often several ‘confirmatory’ tests over months 
and years.[21]  Like others, our study suggests that those who were  newly-diagnosed or more 
vulnerable, such as those who were younger or had an unsupportive partner, were more likely to 
struggle with accepting ART.[22–25]  In all the settings women seemed to go along with what the 
HCWs said even if they did not agree with it, including thinking that HIV testing in the ANC was 
obligatory. This has also been found in several other countries in Africa, including Malawi, Tanzania 
and Uganda.[26–28] 
 
The woman’s role as a mother was a powerful motivator to accept ART even if they did not feel 
entirely ‘ready’, or to continue to attend the ANC despite wanting to avoid HIV-testing or ART-
initiation.  For many women, it appears that the will to protect the infant drove them to overcome 
or ignore other socio-ecological barriers such as poor support, provider attitudes, health facilities 
issues and side effects (data not presented) to be able to continue taking ART.  Like others, we found 
that HCWs presented the protection of the infant as the main objective of Option B+,[25] perhaps 
enabling them to justify their adoption of strong persuasive techniques.  Young age and vulnerability 
due to the pregnancy may have contributed to women’s willingness to obey the HCWs. The 
subservience illustrated by the women’s willingness to obey HCWs without question could be 
attributed to imbalances in: age, education and social status between the patients and providers 
particularly within these social, cultural and political contexts.[28,29]   
 
Once the woman has fulfilled her objective of protecting the baby, not only has her main motivation 
to take ART reduced, but also her reason to attend a clinic and obey the HCWs.  The support she 
received from her partner to attend may diminish, and she might experience further stigma while 
attending the general ART clinic that she did not experience at the ANC.  The concern that women 
will drop out of care after delivering an HIV-negative baby has been expressed in many 
settings.[11,12,30]  We found that HCWs were aware that pressurising women to accept Option B+ 
before they were ready might cause them to default from treatment, however they were 
constrained from giving women more time due to a desire to protect the baby as soon as possible.  
Asymptomatic male and non-pregnant female PLHIV targeted by future ‘test-and-treat’ policies may 
also struggle to accept life-long ART immediately especially without a strong time-bound motivator 
like pregnancy. The absence of this window to protect the infant may mean that HCW also use less 
pressure; which may have implications for treatment engagement in either direction. 
 
There are various strengths and limitations to our study.  As it was nested within a larger study with 
a broader focus, it was not possible to explore all topics relating to Option B+ in the interviews, 
including, for example, women’s and HCW’s views on how to improve the services.  There was a 
potential for social desirability bias in respondents’ accounts (for example wanting to appear as a 
‘good mother’ or a ‘good patient’), however, research assistants were given extensive training with a 
specific focus on developing rapport and trust with the participants to reduce this.  Although HDSS 
populations may differ from the general population, a key strength of the study was our ability to 
draw on data from four areas: we found striking similarities in the issues that emerged across the 
different settings, making it likely that our findings can be generalised to pregnant women in other 
rural populations in sub-Saharan Africa; though urban populations may be different.  Furthermore, 
through our use of the HDSS datasets, we could identify women who had refused Option B+ or had 
stopped taking ART, who are often omitted from studies that rely on sampling frameworks from 
clinic registers. However, these women tended to be difficult to interview: despite efforts to 
reassure them, some women displayed similar avoidance tactics as they might use to avoid taking 
the ART.  Due to the need to disclose their HIV status to the interviewer, women who had not 
accepted their positive HIV status would have been missed by this study: it would also be important 
to understand why such women totally disengage from care. 
 
CONCLUSIONS 
 
We have shown that being pregnant and one’s role as a mother was an overwhelming, yet time-
limited influence on acceptance and adherence to Option B+ in these settings in Malawi, Tanzania 
and Uganda.  To combat the higher attrition rates in pregnant women starting ART due to Option B+, 
women may benefit from being given more time to accept their status and receiving counselling 
tailored to their specific needs with a focus on more sustainable reasons for taking the ART, such as 
their own health and protecting future pregnancies, especially in high-fertility areas.  Other PLHIV 
may have a similar range of factors influencing their readiness to start ART immediately following a 
positive HIV test.  The absence of such a strong motivator to protect the unborn child and the link to 
specific tailored ANC services may further hamper abilities to overcome these barriers: this should 
be borne in mind when implementing ‘test-and-treat’ policies. 
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